Background: Clozapine, the classic atypical neuroleptic, exerts therapeutic actions in schizophrenic patients un-
INTRODUCTION
Clozapine is an important therapeutic agent in treating schizophrenia. Though developed as a neuroleptic, it is unique in its therapeutic profile and may provide major benefits to patients who are resistant to other neuroleptics (1, 2) . Even in patients who respond to conventional neuroleptics, clozapine may be more efficacious (2) . Clozapine appears to relieve negative symptoms, including apathy and emotional withdrawal, that resist conventional neuroleptics and displays a very low incidence of extrapyramidal side effects (EPS). Diminished EPS and greater therapeutic efficacy are also man-
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To explain the greater antischizophrenic actions of atypical neuroleptics, researchers have evaluated effects of these drugs at novel sites. Thus, clozapine displays uniquely high affinity for dopamine D4 receptors (9) . Serotonin 5HT2 receptors have also been implicated. Ritanserin, a selective 5HT2 antagonist, decreases EPS elicited by haloperidol (10) . Mianserin, also a 5HT2 antagonist, relieves negative symptoms in schizophrenics receiving conventional neuroleptics (11) . Compared with conventional neuroleptics, atypical drugs tend to have higher affinities for 5HT2 than D2 receptors (12) . However, there are exceptions such as chlorpromazine and amoxapine, both more potent at 5HT2 than D2 sites (13) .
To assess clozapine actions at various receptors, most studies have evaluated clozapine's potency in competing for the binding of radioligands. However, ligands exert "induced fit", altering receptor conformation so that the potency of a drug in competing for binding of a radioligand may not faithfully reflect that drug's propensity to bind to the receptor in vivo. Ideally, one would like to specify the receptors to which clozapine binds when encountering the human brain in vivo.
To evaluate sites to which clozapine binds preferentially, we have examined the binding of Data in Panel a were plotted using Cricketgraph.
Shown are total (----@----), nonspecific (----LO----), and specific (----U-- IRoth et al. (30) mRuatetal. (31) nShen et al. Compared with conventional neuroleptics, clozapine and other atypical neuroleptics display two unique properties, a low incidence of EPS and greater therapeutic efficacy for negative and possibly even for positive symptoms of schizophrenics. This enhanced efficacy was first shown in patients resistant to conventional neuroleptics (1), but may hold for nonresistant patients as well (1, 36 (37) and other atypical neuroleptics (13, 38, 39) slow Alo but not Ag cells could explain the lowered EPS incidence associated with clozapine. Metabolic measures showing greater dopamine release in the corpus striatum following atypical than conventional neuroleptics support the neurophysiologic data (36, 40) . A link to 5HT2 receptors comes from observations that combinations of the 5HT2 selective drug ritanserin and the D2 antagonist haloperidol elicit striatal dopamine metabolic patterns resembling clozapine (41) . Similarly, administration of ritanserin alleviates EPS provoked by haloperidol (10 
